-
公开(公告)号:US20210139472A1
公开(公告)日:2021-05-13
申请号:US17110465
申请日:2020-12-03
申请人: Franz Dürrenberger , Michael Burgert , Susanna Burckhardt , Wilm Buhr , Aris Kalogerakis , Stefan Reim , Vania Manolova , Susan Boyce , Christopher John Yarnold , Paula Pena , Jon Shepard , Cristina Lecci , Richard Jarjes-Pike , John Scott
发明人: Franz Dürrenberger , Michael Burgert , Susanna Burckhardt , Wilm Buhr , Aris Kalogerakis , Stefan Reim , Vania Manolova , Susan Boyce , Christopher John Yarnold , Paula Pena , Jon Shepard , Cristina Lecci , Richard Jarjes-Pike , John Scott
IPC分类号: C07D413/14 , A61K31/4184 , A61K31/427 , A61K31/4355 , A61K31/437 , A61K31/4375 , A61K31/4439 , A61K31/444 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/55 , C07D417/14 , C07D471/04 , C07D401/14 , C07D417/12 , A61K31/426 , A61K31/435 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K45/06 , C07D277/56 , A61P7/06 , A61P25/28 , A61P25/16 , A61P3/12 , C07D403/14 , C07D413/04 , C07D487/04
摘要: The invention relates to novel compounds of the general formula (I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.